HOOK1 Inhibits the Progression of Renal Cell Carcinoma via TGF‐β and TNFSF13B/VEGF‐A Axis

Accumulating evidence shows HOOK1 disordered in human malignancies. However, the clinicopathological and biological significance of HOOK1 in renal cell carcinoma (RCC) remains rarely studied. In this study, the authors demonstrate that HOOK1 is downregulated in RCC samples with predicted poorer clinical prognosis. Mechanistically, HOOK1 inhibits tumor growth and metastasis via canonical TGF-β/ALK5/p-Smad3 and non-canonical TGF-β/MEK/ERK/c-Myc pathway. At the same time, HOOK1 inhibits RCC angiogenesis and sunitinib resistance by promoting degradation of TNFSF13B through the ubiquitin-proteasome pathway. In addition, HOOK1 is transcriptionally regulated by nuclear factor E2F3 in VHL dependent manner. Notably, an agonist of HOOK1, meletin, is screened and it shows antitumor activity more effectively when combined with sunitinib or nivolumab than it is used alone. The findings reveal a pivotal role of HOOK1 in anti-cancer treatment, and identify a novel therapeutic strategy for renal cell carcinoma.

[1]  Hong Liu,et al.  Identification and characterization of sex‐dependent gene expression profile in glioblastoma , 2022, Neuropathology : official journal of the Japanese Society of Neuropathology.

[2]  Shan Feng,et al.  Multi-Omics Profiling to Assess Signaling Changes upon VHL Restoration and Identify Putative VHL Substrates in Clear Cell Renal Cell Carcinoma Cell Lines , 2022, Cells.

[3]  P. Blin,et al.  Incidence and risk of cancer among multiple sclerosis patients: A matched population‐based cohort study , 2021, European journal of neurology.

[4]  Guijuan Zhang,et al.  To explore immune synergistic function of Quercetin in inhibiting breast cancer cells , 2021, Cancer cell international.

[5]  Q. Cheng,et al.  TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas , 2021, Frontiers in Immunology.

[6]  Fukang Sun,et al.  High TNFSF13B expression as a predictor of poor prognosis in adrenocortical carcinoma , 2021, Translational andrology and urology.

[7]  A. Silk,et al.  Optimal timing of PD-1 blockade in combination with oncolytic virus therapy. , 2021, Seminars in cancer biology.

[8]  D. Süsskind,et al.  Exploring the role of BAFF as biomarker in the detection of uveal melanoma metastases , 2021, Journal of Cancer Research and Clinical Oncology.

[9]  S. Oudard,et al.  Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) , 2021, Cancers.

[10]  Jeffrey T. Chang,et al.  EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures , 2020, British Journal of Cancer.

[11]  J. Ge,et al.  Alpha-lipoic acid protects against pressure overload-induced heart failure via ALDH2-dependent Nrf1-FUNDC1 signaling , 2020, Cell Death & Disease.

[12]  Ashton C. Berger,et al.  Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma , 2020, Nature Medicine.

[13]  P. Hegde,et al.  High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade , 2020, Nature Medicine.

[14]  Rong-hao Wang,et al.  SH3BGRL2 inhibits growth and metastasis in clear cell renal cell carcinoma via activating hippo/TEAD1-Twist1 pathway , 2020, EBioMedicine.

[15]  D. Chan,et al.  Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers. , 2019, Seminars in cancer biology.

[16]  Le-Bin Song,et al.  The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis , 2018, Arthritis Research & Therapy.

[17]  L. Kiemeney,et al.  Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus , 2018, Scientific Reports.

[18]  R. Motzer,et al.  CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. , 2017, European urology.

[19]  K. Shokat,et al.  Drugging the 'undruggable' cancer targets , 2017, Nature Reviews Cancer.

[20]  Leaf Huang,et al.  Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles. , 2017, ACS nano.

[21]  S. Ku,et al.  Engineering of cell microenvironment-responsive polypeptide nanovehicle co-encapsulating a synergistic combination of small molecules for effective chemotherapy in solid tumors. , 2017, Acta biomaterialia.

[22]  J. Cheville,et al.  Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  U. Harmenberg,et al.  Perivascular PDGFR-β is an independent marker for prognosis in renal cell carcinoma , 2016, British Journal of Cancer.

[24]  E. Perlman,et al.  Expanding the spectrum of ALK‐rearranged renal cell carcinomas in children: Identification of a novel HOOK1‐ALK fusion transcript , 2016, Genes, chromosomes & cancer.

[25]  D. Nam,et al.  Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma , 2016, Genome Biology.

[26]  C. Thoma.  Kidney cancer: S1P—a promising target in sunitinib-resistant RCC , 2015, Nature Reviews Urology.

[27]  E. Maher,et al.  VHL, the story of a tumour suppressor gene , 2014, Nature Reviews Cancer.

[28]  Wei Zhou,et al.  TCMSP: a database of systems pharmacology for drug discovery from herbal medicines , 2014, Journal of Cheminformatics.

[29]  Kakajan Komurov,et al.  Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes , 2010, Proceedings of the National Academy of Sciences.

[30]  O. L. Mohr.  The Second Chromosome Recessive Hook Bristles in Drosophila Melanogaster , 2010 .

[31]  A. Ghanate,et al.  Snail and Slug Mediate Radioresistance and Chemoresistance by Antagonizing p53‐Mediated Apoptosis and Acquiring a Stem‐Like Phenotype in Ovarian Cancer Cells , 2009, Stem cells.

[32]  J. Massagué,et al.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. , 2005, Cancer cell.

[33]  W. Schulz,et al.  Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer , 2005, Molecular Cancer.

[34]  M. West,et al.  Gene expression phenotypic models that predict the activity of oncogenic pathways , 2003, Nature Genetics.

[35]  H. Krämer,et al.  Genetic analysis of hook, a gene required for endocytic trafficking in drosophila. , 1999, Genetics.